Gene Therapy Grants

Jackson Gabriel Silver Dystrophic Epidermolysis Bullosa Career
Development Award
This award is offered for the first time in 2009 and is funded by a generous gift from the
Grossmann/Silver family. It is intended to assist an individual in the transition from
fellowship to established investigator. It provides career development support for a
junior investigator pursuing research that has significant potential to benefit the study and
treatment of recessive dystrophic epidermolysis bullosa. The ultimate goal of the
proposed research is to provide new efficacious treatment modalities, and ultimately a
cure for the patients suffering from recessive dystrophic EB.
The proposed research must relate to and benefit the study of recessive dystrophic
epidermolysis bullosa. Research areas may include, but are not limited to molecular
diagnostics; skin repair and tissue regeneration; molecular therapies, including gene-,
cell- and protein-based approaches; stem cell research; tissue engineering; and other
novel approaches
Applicant Eligibility Requirements:
• M.D.; M.D., Ph.D.; Ph.D.; or D.O. degree
• Appropriate initial training in biomedical research (i.e., two to three-year
fellowship or postdoctoral training)
• Junior faculty member in a department or division of dermatology or another
program at the sponsoring institution that is approved by the dermatology
chair, through an Assistant Professor level, at the time of funding
• Junior investigator in the early stages of his/her career
• Demonstrates a strong commitment to skin research
• Strong institutional commitment for the individual’s career development
• NOT a recipient of an NIH career development award

To meet the application deadline, can my application be postmarked by October 15th?
No. To be considered for a 2009 research award, your complete research application must be
sent so that it is RECEIVED at the Foundation office on or before Wednesday, October 15,
2008. Your application should be sent to the following address:
Medical and Scientific Committee
Dermatology Foundation
1560 Sherman Avenue, Suite 870
Evanston, IL 60201-4808

Research grants

The focus of the Hereditary Disease Foundation is on Huntington's disease. Support will be for research projects that will contribute to identifying and understanding the basic defect in Huntington's disease. Areas of interest include trinucleotide expansions, animal models, gene therapy, neurobiology and development of the basal ganglia, cell survival and death, and intercellular signaling in striatal neurons.

Anyone accepting funding from the Hereditary Disease Foundation must agree to abide by the following policy: Propagatable materials (including monoclonal antibodies and recombinant DNAs) should be freely available to other investigators following publication. The Foundation's position is that there be no restrictions or proprietary rights in materials produced with our support.

Deadlines for applications are February 15, June 15 and October 15. Applications will be reviewed in May, September and January. To obtain an application, please submit a letter of intent no more than one page long. It may be submitted at any time to following address,

Hereditary Disease Foundation
Attn: Carl D. Johnson, PhD
3960 Broadway, 6th Floor
New York, NY 10032
USA

The maximum award for research grants is $50,000. Grants are usually for one year with a possibility of renewal. Grants are considered seed money. If the project shows promise, it is hoped that other institutions will fund it thereafter. The Foundation does not generally include the salary of the principle investigator. Indirect costs are not allowed, but fringe benefits are considered part of personnel costs and are allowed.

Grant applications should be submitted by email and five hard copies. Supplemental material and reprints should be submitted with a file type of PDF(.pdf).

Applicants are notified of funding decisions by letter only.

To apply:

· Submit a letter of intent: There is no deadline – submit anytime, electronically using the form on the Foundation’s website:
http://www.hdfoundation.org/funding/intent.php.

The letter of intent should include:

o Contact information

o A summary of your proposed research project – 500 words or less

· Letter of Intent Review: Letters of intent are reviewed by a triage group. Turn-around is usually less than two weeks and the primary consideration is relevance to finding treatments and cures for Huntington’s disease. If a proposal is accepted, an application form for a full proposal is sent to the applicant by email. Applicants are encouraged to interact by email or phone with Carl Johnson, Ph.D., the Executive Director for Science, while preparing their application

Applications require:

· Administrative contact: Name, title, email address, phone & fax numbers and mailing address of the institutional representative who will manage the project. The application must be approved and signed by the institution.

· Project summary: Not to exceed 200 words.

· Budget (for Grants only): Grant funding is limited to $50,000. Except in unusual circumstances, salary support is not provided for the Principal Investigator. The Foundation does not provide funds for indirect costs or overhead. Postdoctoral Fellowship salaries are determined by the Foundation, based on number of years after receipt of a doctoral degree. Postdoctoral Fellowship Awards include $8,000 for supplies.

· Other current and pending support: Please provide a complete list (NIH format) indicating aims of each project and potential overlap with the current proposal.

· Biographical sketch: Attach a two-page biographical sketch (NIH format) for the Principal Investigator and other professional personnel. Include training, experience, recent publications and patent filings. Any supplemental materials, manuscripts or papers should be submitted electronically in PDF format.

· Protection of Human Subjects: Any study using human subjects must be approved by the Institutional Review Board (IRB) of the applicant institution. Please attach the completed “Protection of Human Subjects Assurance/Certification/Declaration” form.

· Protection of Animal Subjects: The transportation, care, and use of animals must be in accordance with the Animal Welfare Act (7 U.S.C. 2131 et. seq.) and other applicable Federal laws, guidelines, and policies.

· Study Proposal: Not to exceed 10 pages, including references. There is no need for an extensive, NIH style, introduction, but be sure to include a description of critical details of the proposed plan as well as documentation of research experience. Particular attention should be paid to the aims and anticipated outcomes of the study and on how they will help discover or develop treatments for Huntington’s disease.

Application Review:

Applications are reviewed by the Scientific Advisory Board of the Hereditary Disease Foundation. The SAB meets three times each year: in January, May and October. Applications received at least six weeks prior to the meeting are considered. Applicants will receive written notification of the funding decision shortly after the review meeting.

Award Payment:

If the application is approved for funding, payment will be made in two equal installments. Awardees must arrange, via email or in writing, activation of the Award. The first payment is sent immediately; the second will be made six months later, upon receipt of a progress report via email. A final report including a financial statement is also required.

Please submit completed applications both by email and five hard copies to:

Hereditary Disease Foundation
Attn: Carl D. Johnson, Ph.D.
Executive Director for Science
3960 Broadway, 6th Floor
New York, NY 10032

John J. Wasmuth Postdoctoral Fellowships

The John J. Wasmuth postdoctoral fellowships are named in honor of the late John Jacob Wasmuth who was an essential member of the Huntington's Disease Collaborative Research Group and a long-term and valued member of our Scientific Advisory Board. John was a superb mentor. It is our hope that those granted fellowships bearing his name will seek the same level of creativity, imagination, rigor and esprit de corps that characterized John.

The Hereditary Disease Foundation offers support for research projects that will contribute to identifying and understanding the basic defect of Huntington's disease. Areas of interest include trinucleotide expansions, animal models, gene therapy, neurobiology and development of the basal ganglia, cell survival and death, and intercellular signaling in striatal neurons.

Anyone accepting funding from the Hereditary Disease Foundation must agree to abide by the following policy: Propagatable materials (including monoclonal antibodies and recombinant DNAs) should be freely available to other investigators following publication. The Foundation's position is that there be no restrictions or proprietary rights in materials produced with our support.

Deadlines for applications are February 15, June 15 and October 15. Applications will be reviewed in May, September and January. All John Wasmuth Fellowships are automatically considered in January of every year for the Milton Wexler Fellowship award.

To obtain an application, please submit a letter of intent no more than one page long. It may be submitted at any time to the following address,

Hereditary Disease Foundation
Attn: Carl D. Johnson, PhD
3960 Broadway, 6th Floor
New York, NY 10032
USA

John J. Wasmuth Postdoctoral Fellowship awards are based on the following scale which includes all university fringe benefits plus $8,000 for supplies:

0 years since Ph.D. = Stipend of $40,500

1 year since Ph.D. = Stipend of $43,000

2 years since Ph.D. = Stipend of $46,000

3 years since Ph.D. = Stipend of $48,200

4 years since Ph.D. = Stipend of $50,200

5 years since Ph.D. = Stipend of $52,400

6 years since Ph.D. = Stipend of $54,500

7 years since Ph.D. = Stipend of $56,000
Indirect costs are not allowed, but fringe benefits are considered part of personnel costs and are permitted.

Funded fellowships will be renewed for a second year, subject to satisfactory progress reports.

The completed application packet will consist of the application, the curriculum vitae of the applicant and the applicant’s research sponsor, a letter of support from the sponsor, and two letters of recommendation from two others familiar with the applicant, one of whom is normally the applicant’s PhD. sponsor.

Note: Completed applications should be submitted by email and five (5) hardcopies. Supplemental material and reprints should be submitted with a file type of PDF (.pdf).

Applicants are notified of funding decisions by letter only.

A list of previous Postdoctoral Fellows is available on request.

Hereditary Disease Foundation
3960 Broadway, 6th Floor
New York, NY 10032
Voice: (212) 928-2121
Fax: (212) 928-2172

http://www.hdfoundation.org

Please feel free to contact the Hereditary Disease Foundation by phone at
1 (212) 928-2121 with questions or comments regarding the application process

Gateway for Cancer Research is dedicated to curing cancer through funding innovative patient-centered clinical studies that make an impact on those battling cancer.
Preliminary Grant Request
PURPOSE:

The overall goal of the Clinical Investigation Grant Program of Gateway for Cancer Research (Gateway) is to stimulate innovative research relevant to cancer therapy (e.g., new agents, immunotherapy, biological response modifiers, gene therapy), clinical nutrition, and cancer integrative medicine. The Organization supports innovative clinical research in conventional as well as integrative therapies. The Clinical Investigation Grant Program is a mechanism to encourage investigators directly focused on clinical problems and clinical applications of basic research in phase I/II research studies. Gateway is particularly interested in identifying and funding these groups of researchers:

1.

Young investigators working in established research programs relevant to clinical research that are without support from the NIH or other cancer research agencies.
2. Established clinical researchers who wish to embark on innovative studies directly relevant to the mission of Gateway with novel, new, or pilot projects distinctly removed from their currently funded research projects.

PLEASE NOTE

The Organization will not support extensions of conventional or traditional chemotherapy such as Phase III/IV trials. Also, basic research and pre-clinical research in animals will not be supported. Diagnostic trials if submitted, must contain a mechanism for measuring patient impact. The primary consideration in granting support is to improve treatment options for cancer patients while advancing toward a cure. The Organization is not a traditional source of funds and believes that many other resources are available for incremental improvements in cancer therapy. The Organization will support truly innovative and unique research that has the potential to impact the lives of cancer patients in a positive way at the earliest opportunity.

Patient Impact as defined by Gateway: a study in which an intervention is provided to a patient so that an outcome may be analyzed from the research study design.

2008 - 2009 Gateway Grant Submission Schedule
Preliminary Grant Applications Due Formal Applications Due (submission by invitation only) Award Notification
June 2, 2008 July 14, 2008 August 29, 2008
August 11, 2008 September 8, 2008 November 10, 2008
November 5, 2008 December 10, 2008 January 28, 2009
January 28, 2009 March 4, 2009 April 22, 2009

*Please note: applications are due by close of business Central Standard Time.

ELIGIBILITY:

New, as well as established investigators are encouraged to apply. Established investigators requesting pilot funds should show how their project is a departure from on-going, funded work. New projects may be an extension of other work but cannot overlap any funded projects unless the applicant clearly demonstrates that new funding will not duplicate existing support.

USE OF FUNDS:

The Principal Investigator and other key personnel may use awarded funds to support the proportion of salary devoted to the project. Funds may be used for supplies and non-reimbursable research-related patient care costs, including extraordinary laboratory and imaging studies. Travel is not covered in the first year. Equipment will be funded only in extremely rare circumstances. Such requests should be fully justified in the budget.

MAXIMUM AWARD:

Grants from the Organization are limited. There can be no overlap of funds with existing sources. The amount of the award varies with the availability of funds. Awards range between $25,000 and $300,000/year, including indirect expenses, for two years. Investigators receiving a two-year award must submit a progress report in order to receive a second year of funding.

Contact Us

To find out more about Gateway you may contact us by telephone at 847-342-7450.

Our Mailing Address is:

Gateway for Cancer Research
1336 Basswood Road
Schaumburg, Illinois 60173

Gateway for Cancer Research is dedicated to curing cancer through funding innovative patient-centered clinical studies that make an impact on those battling cancer.
Preliminary Grant Request
PURPOSE:

The overall goal of the Clinical Investigation Grant Program of Gateway for Cancer Research (Gateway) is to stimulate innovative research relevant to cancer therapy (e.g., new agents, immunotherapy, biological response modifiers, gene therapy), clinical nutrition, and cancer integrative medicine. The Organization supports innovative clinical research in conventional as well as integrative therapies. The Clinical Investigation Grant Program is a mechanism to encourage investigators directly focused on clinical problems and clinical applications of basic research in phase I/II research studies. Gateway is particularly interested in identifying and funding these groups of researchers:

1.

Young investigators working in established research programs relevant to clinical research that are without support from the NIH or other cancer research agencies.
2. Established clinical researchers who wish to embark on innovative studies directly relevant to the mission of Gateway with novel, new, or pilot projects distinctly removed from their currently funded research projects.

PLEASE NOTE

The Organization will not support extensions of conventional or traditional chemotherapy such as Phase III/IV trials. Also, basic research and pre-clinical research in animals will not be supported. Diagnostic trials if submitted, must contain a mechanism for measuring patient impact. The primary consideration in granting support is to improve treatment options for cancer patients while advancing toward a cure. The Organization is not a traditional source of funds and believes that many other resources are available for incremental improvements in cancer therapy. The Organization will support truly innovative and unique research that has the potential to impact the lives of cancer patients in a positive way at the earliest opportunity.

Patient Impact as defined by Gateway: a study in which an intervention is provided to a patient so that an outcome may be analyzed from the research study design.

2008 - 2009 Gateway Grant Submission Schedule
Preliminary Grant Applications Due Formal Applications Due (submission by invitation only) Award Notification
June 2, 2008 July 14, 2008 August 29, 2008
August 11, 2008 September 8, 2008 November 10, 2008
November 5, 2008 December 10, 2008 January 28, 2009
January 28, 2009 March 4, 2009 April 22, 2009

*Please note: applications are due by close of business Central Standard Time.

ELIGIBILITY:

New, as well as established investigators are encouraged to apply. Established investigators requesting pilot funds should show how their project is a departure from on-going, funded work. New projects may be an extension of other work but cannot overlap any funded projects unless the applicant clearly demonstrates that new funding will not duplicate existing support.

USE OF FUNDS:

The Principal Investigator and other key personnel may use awarded funds to support the proportion of salary devoted to the project. Funds may be used for supplies and non-reimbursable research-related patient care costs, including extraordinary laboratory and imaging studies. Travel is not covered in the first year. Equipment will be funded only in extremely rare circumstances. Such requests should be fully justified in the budget.

MAXIMUM AWARD:

Grants from the Organization are limited. There can be no overlap of funds with existing sources. The amount of the award varies with the availability of funds. Awards range between $25,000 and $300,000/year, including indirect expenses, for two years. Investigators receiving a two-year award must submit a progress report in order to receive a second year of funding.

Contact Us

To find out more about Gateway you may contact us by telephone at 847-342-7450.

Our Mailing Address is:

Gateway for Cancer Research
1336 Basswood Road
Schaumburg, Illinois 60173